Prescribing an unapproved new drug outside a trial is technically illegal under the FDCA (aside from narrow compassionate-use exceptions)
The two short-acting GLP-1 RAs, exenatide BID and lixisenatide, both caused a maximum HR increase of 810 bpm 24 h after injection, which returned to baseline levels after approximately 1012 h (Sanofi, data on file [available on request [22] ] and [19, 20]), with a mean 24-h HR increase of approximately 12 bpm for both preparations
The cohort was 82.4% female, with a median age of 52
Like Calibrate, they focus primarily on prescribing brand-name GLP-1s and coordinating prior authorizations with commercial insurance
In my experience, clients see benefits with anxiety, insomnia, menstrual cramps, and even migraines/headaches, within the first week